ID

22694

Descripción

Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.; ODM derived from: https://clinicaltrials.gov/show/NCT00554086

Link

https://clinicaltrials.gov/show/NCT00554086

Palabras clave

Versiones (1)
  1. 9/6/17 9/6/17 -
Subido en

9 de junio de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT00554086

Inglés

Eligibility Prostate Cancer NCT00554086

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. provision of written informed consent.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
2. men, over 18 years of age, with histologically-confirmed prostate cancer
Descripción

Gender | Age | Prostate carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0600139
3. treatment with zoladex (goserelin acetate) for greater than 3 months prior to day 1
Descripción

Zoladex | Goserelin Acetate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0149473
UMLS CUI [2]
C0700476
4. serum testosterone level < 50 ng/ml
Descripción

Serum testosterone measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428413
5. current treatment with bicalutamide 50 mg daily.**
Descripción

Bicalutamide U/day

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0285590
UMLS CUI [1,2]
C0456683
6. two consecutive rises in psa above a nadir value, with the absolute value of the latest psa > 2.0 ng/ml.
Descripción

Raised prostate specific antigen Findings Quantity | Prostate specific antigen measurement Most Recent Absolute value

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0178415
UMLS CUI [1,2]
C2607943
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C0201544
UMLS CUI [2,2]
C1513491
UMLS CUI [2,3]
C0205344
7. highest psa level no greater than or equal to 30 ng/ml.
Descripción

Prostate specific antigen measurement Highest

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0201544
UMLS CUI [1,2]
C1522410
8. life expectancy of greater than 1 year -
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients may not have received prolonged anti-androgen therapy other than with bicalutamide. patients who have received short term (2 months or less) non-steroidal anti-androgen therapy with an agent other than bicalutamide to block flare are not excluded.*
Descripción

Antiandrogen therapy Prolonged | bicalutamide | Nonsteroidal Anti-Androgens short-term

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0279492
UMLS CUI [1,2]
C0439590
UMLS CUI [2]
C0285590
UMLS CUI [3,1]
C1320169
UMLS CUI [3,2]
C0443303
2. psa level greater than 30 ng/ml.
Descripción

Prostate specific antigen measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201544
3. in the opinion of the investigator, any evidence of severe or uncontrolled systemic disease which would make it undesirable for the patient to participate in the trial.
Descripción

Systemic disease Severe Study Subject Participation Status Inappropriate | Systemic disease Uncontrolled Study Subject Participation Status Inappropriate

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0442893
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C2348568
UMLS CUI [1,4]
C1548788
UMLS CUI [2,1]
C0442893
UMLS CUI [2,2]
C0205318
UMLS CUI [2,3]
C2348568
UMLS CUI [2,4]
C1548788
4. subjects who have received prior chemotherapy.
Descripción

Chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
5. other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
Descripción

Malignant Neoplasms | Basal cell carcinoma | Transitional cell carcinoma of bladder Superficial

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0007117
UMLS CUI [3,1]
C0279680
UMLS CUI [3,2]
C0205124
6. absolute neutrophil count less than 1.5 x 109/l or platelets less than 100 x 109/l.
Descripción

Absolute neutrophil count | Platelet Count measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0032181
7. serum bilirubin greater than 1.25 times the upper limit of reference range (ulrr).
Descripción

Elevated total bilirubin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0741494
8. alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 2.5 times the ulrr.
Descripción

Alanine aminotransferase increased | Aspartate aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
9. serum creatinine greater than 1.5 times -
Descripción

Serum creatinine raised

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0700225
Volver a la parte superior de la página

Similar models

Eligibility Prostate Cancer NCT00554086

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. provision of written informed consent.
boolean
C0021430 (UMLS CUI [1])
Gender | Age | Prostate carcinoma
Item
2. men, over 18 years of age, with histologically-confirmed prostate cancer
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0600139 (UMLS CUI [3])
Zoladex | Goserelin Acetate
Item
3. treatment with zoladex (goserelin acetate) for greater than 3 months prior to day 1
boolean
C0149473 (UMLS CUI [1])
C0700476 (UMLS CUI [2])
Serum testosterone measurement
Item
4. serum testosterone level < 50 ng/ml
boolean
C0428413 (UMLS CUI [1])
Bicalutamide U/day
Item
5. current treatment with bicalutamide 50 mg daily.**
boolean
C0285590 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
Raised prostate specific antigen Findings Quantity | Prostate specific antigen measurement Most Recent Absolute value
Item
6. two consecutive rises in psa above a nadir value, with the absolute value of the latest psa > 2.0 ng/ml.
boolean
C0178415 (UMLS CUI [1,1])
C2607943 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0201544 (UMLS CUI [2,1])
C1513491 (UMLS CUI [2,2])
C0205344 (UMLS CUI [2,3])
Prostate specific antigen measurement Highest
Item
7. highest psa level no greater than or equal to 30 ng/ml.
boolean
C0201544 (UMLS CUI [1,1])
C1522410 (UMLS CUI [1,2])
Life Expectancy
Item
8. life expectancy of greater than 1 year -
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Antiandrogen therapy Prolonged | bicalutamide | Nonsteroidal Anti-Androgens short-term
Item
1. patients may not have received prolonged anti-androgen therapy other than with bicalutamide. patients who have received short term (2 months or less) non-steroidal anti-androgen therapy with an agent other than bicalutamide to block flare are not excluded.*
boolean
C0279492 (UMLS CUI [1,1])
C0439590 (UMLS CUI [1,2])
C0285590 (UMLS CUI [2])
C1320169 (UMLS CUI [3,1])
C0443303 (UMLS CUI [3,2])
Prostate specific antigen measurement
Item
2. psa level greater than 30 ng/ml.
boolean
C0201544 (UMLS CUI [1])
Systemic disease Severe Study Subject Participation Status Inappropriate | Systemic disease Uncontrolled Study Subject Participation Status Inappropriate
Item
3. in the opinion of the investigator, any evidence of severe or uncontrolled systemic disease which would make it undesirable for the patient to participate in the trial.
boolean
C0442893 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C1548788 (UMLS CUI [1,4])
C0442893 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C1548788 (UMLS CUI [2,4])
Chemotherapy
Item
4. subjects who have received prior chemotherapy.
boolean
C0392920 (UMLS CUI [1])
Malignant Neoplasms | Basal cell carcinoma | Transitional cell carcinoma of bladder Superficial
Item
5. other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0279680 (UMLS CUI [3,1])
C0205124 (UMLS CUI [3,2])
Absolute neutrophil count | Platelet Count measurement
Item
6. absolute neutrophil count less than 1.5 x 109/l or platelets less than 100 x 109/l.
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
Elevated total bilirubin
Item
7. serum bilirubin greater than 1.25 times the upper limit of reference range (ulrr).
boolean
C0741494 (UMLS CUI [1])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
8. alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 2.5 times the ulrr.
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Serum creatinine raised
Item
9. serum creatinine greater than 1.5 times -
boolean
C0700225 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial